Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Spectrum and Genetics of Ocular Manifestations in Muscle Eye Brain Disease: A Literature Review.

Seminars in ophthalmology·2026
Same author

Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials.

American journal of ophthalmology·2026
Same author

Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model.

Molecular therapy. Advances·2026
Same author

Optogenetics for therapeutic use in the brain, eye, and ear.

Handbook of clinical neurology·2026
Same author

Centripetal Retinal Degeneration Follows an Exponential Decay and May Be Reversed Following Gene Therapy.

American journal of ophthalmology·2026
Same author

Single-cell and spatial transcriptomic analyses of gene therapy-associated retinal inflammation in non-human primates.

Molecular therapy. Advances·2026

Related Experiment Video

Updated: May 15, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Gene therapy for retinal disease.

Michelle E McClements1, Robert E MacLaren

  • 1Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Translational Research : the Journal of Laboratory and Clinical Medicine
|January 12, 2013
PubMed
Summary
This summary is machine-generated.

Gene therapy using adeno-associated viral (AAV) vectors shows promise for treating inherited retinal diseases, potentially preventing blindness. Clinical trials indicate AAV vectors are safe and effective, with future advancements expected.

More Related Videos

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
05:09

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye

Published on: November 25, 2012

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Related Experiment Videos

Last Updated: May 15, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
05:09

Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye

Published on: November 25, 2012

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Area of Science:

  • Ophthalmology
  • Genetics
  • Molecular Biology

Background:

  • Inherited retinal diseases cause progressive vision loss and blindness.
  • Gene therapy offers a potential therapeutic strategy for these conditions.
  • Adeno-associated viral (AAV) vectors are a leading platform for ocular gene delivery.

Purpose of the Study:

  • To review recent advances in AAV vector-based gene therapy for inherited retinal diseases.
  • To highlight the safety and efficacy of AAV vectors in human clinical trials.
  • To discuss future directions and potential improvements in AAV gene therapy for retinal degeneration.

Main Methods:

  • Review of current literature on AAV vector gene therapy for retinal diseases.
  • Analysis of data from human clinical trials.
  • Discussion of advancements in vector targeting, transduction efficiency, and therapeutic augmentation.

Main Results:

  • Human clinical trials demonstrate encouraging safety and efficacy of AAV vectors for retinal gene therapy.
  • Progress has been made in achieving cell-specific targeting and improving transduction efficiency in retinal layers.
  • The use of AAV-delivered growth factors shows potential to enhance therapeutic effects and reduce cell death.

Conclusions:

  • AAV vector-based gene therapy is a rapidly advancing field for treating inherited retinal diseases.
  • Current clinical data support the safety and efficacy of AAV vectors.
  • Future research focusing on enhanced targeting and novel therapeutic approaches holds significant promise for improved outcomes in clinical trials.